Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study.
Adult
Aged
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antineoplastic Agents
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Docetaxel
/ therapeutic use
Female
Humans
Immunotherapy
/ methods
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Retrospective Studies
Ramucirumab
chemoimmunotherapy
docetaxel plus ramucirumab
non-small-cell lung cancer
performance status
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
30
10
2021
received:
27
09
2021
accepted:
01
11
2021
pubmed:
19
11
2021
medline:
8
2
2022
entrez:
18
11
2021
Statut:
ppublish
Résumé
Chemoimmunotherapy has become a standard treatment option for patients with untreated advanced non-small-cell lung cancer (NSCLC). However, numerous patients with advanced NSCLC develop disease progression. Therefore, the selection of second-line treatment after chemoimmunotherapy is crucial for improving clinical outcomes. Of 88 enrolled patients with advanced NSCLC who received chemoimmunotherapy, we retrospectively evaluated 33 who received second-line chemotherapy after progression of chemoimmunotherapy at six centers in Japan. Among them, 18 patients received docetaxel plus ramucirumab and 15 patients received single-agent chemotherapy. The objective response rate in patients treated with docetaxel plus ramucirumab was significantly higher than that in patients treated with a single-agent chemotherapy regimen (55.6% vs. 0%, p < 0.001). The median progression-free survival (PFS) of patients who received docetaxel plus ramucirumab and single-agent chemotherapy was 5.8 months and 5.0 months, respectively (log-rank test p = 0.17). In the docetaxel plus ramucirumab regimen group, patients who responded to chemoimmunotherapy for ≥8.8 months had a significantly longer response to docetaxel plus ramucirumab than those who responded for <8.8 months (not reached vs. 4.1 months, log-rank test p = 0.003). In contrast, in the single-agent chemotherapy group, there was no significant difference in PFS between the ≥8.8- and <8.8-month PFS groups with chemoimmunotherapy (5.0 vs. 1.6 months, log-rank test p = 0.66). Our retrospective observations suggest that the group with longer PFS with chemoimmunotherapy might be expected to benefit from docetaxel plus ramucirumab treatment in second-line settings for patients with advanced NSCLC.
Sections du résumé
BACKGROUND
Chemoimmunotherapy has become a standard treatment option for patients with untreated advanced non-small-cell lung cancer (NSCLC). However, numerous patients with advanced NSCLC develop disease progression. Therefore, the selection of second-line treatment after chemoimmunotherapy is crucial for improving clinical outcomes.
METHODS
Of 88 enrolled patients with advanced NSCLC who received chemoimmunotherapy, we retrospectively evaluated 33 who received second-line chemotherapy after progression of chemoimmunotherapy at six centers in Japan. Among them, 18 patients received docetaxel plus ramucirumab and 15 patients received single-agent chemotherapy.
RESULTS
The objective response rate in patients treated with docetaxel plus ramucirumab was significantly higher than that in patients treated with a single-agent chemotherapy regimen (55.6% vs. 0%, p < 0.001). The median progression-free survival (PFS) of patients who received docetaxel plus ramucirumab and single-agent chemotherapy was 5.8 months and 5.0 months, respectively (log-rank test p = 0.17). In the docetaxel plus ramucirumab regimen group, patients who responded to chemoimmunotherapy for ≥8.8 months had a significantly longer response to docetaxel plus ramucirumab than those who responded for <8.8 months (not reached vs. 4.1 months, log-rank test p = 0.003). In contrast, in the single-agent chemotherapy group, there was no significant difference in PFS between the ≥8.8- and <8.8-month PFS groups with chemoimmunotherapy (5.0 vs. 1.6 months, log-rank test p = 0.66).
CONCLUSION
Our retrospective observations suggest that the group with longer PFS with chemoimmunotherapy might be expected to benefit from docetaxel plus ramucirumab treatment in second-line settings for patients with advanced NSCLC.
Identifiants
pubmed: 34791812
doi: 10.1111/1759-7714.14236
pmc: PMC8758423
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents
0
Docetaxel
15H5577CQD
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
173-181Informations de copyright
© 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Lancet Oncol. 2021 Feb;22(2):198-211
pubmed: 33476593
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
CA Cancer J Clin. 2018 Nov;68(6):425-445
pubmed: 30285281
Oncoimmunology. 2021 Jul 8;10(1):1950411
pubmed: 34290909
Asian Pac J Cancer Prev. ;18(5):1417-1421
pubmed: 28612596
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94
pubmed: 29115304
J Clin Oncol. 2000 May;18(10):2095-103
pubmed: 10811675
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Clin Lung Cancer. 2018 Sep;19(5):e721-e734
pubmed: 29934133
Lung Cancer. 2011 Sep;73(3):338-44
pubmed: 21296449
Lung Cancer. 2016 Sep;99:186-93
pubmed: 27565938
Transl Lung Cancer Res. 2019 Aug;8(4):450-460
pubmed: 31555518
ESMO Open. 2020 Jan;5(1):
pubmed: 31958290
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Nat Rev Clin Oncol. 2018 May;15(5):325-340
pubmed: 29508855
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
N Engl J Med. 2020 Aug 13;383(7):640-649
pubmed: 32786189
J Thorac Oncol. 2021 Sep;16(9):1523-1532
pubmed: 33915251
Br J Cancer. 2004 May 4;90(9):1704-6
pubmed: 15150622
Thorac Cancer. 2022 Jan;13(2):173-181
pubmed: 34791812
Transl Lung Cancer Res. 2021 Apr;10(4):1642-1652
pubmed: 34012781
Thorac Cancer. 2019 Apr;10(4):775-781
pubmed: 30809973
Transl Lung Cancer Res. 2021 Jul;10(7):3093-3105
pubmed: 34430350
Lung Cancer. 2019 Oct;136:45-51
pubmed: 31437663
Ann Oncol. 2017 Nov 1;28(11):2698-2706
pubmed: 29045553
Lancet. 2014 Aug 23;384(9944):665-73
pubmed: 24933332